Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

ROS modifiers and NOX4 affect the expression of the survivin-associated radio-adaptive response.

Murley JS, Arbiser JL, Weichselbaum RR, Grdina DJ.

Free Radic Biol Med. 2018 Aug 1;123:39-52. doi: 10.1016/j.freeradbiomed.2018.04.547. Epub 2018 Apr 13.

PMID:
29660403
2.

TP53 Mutational Status and ROS Effect the Expression of the Survivin-Associated Radio-Adaptive Response.

Murley JS, Miller RC, Weichselbaum RR, Grdina DJ.

Radiat Res. 2017 Nov;188(5):579-590. doi: 10.1667/RR14831.1. Epub 2017 Aug 16.

3.

Altered expression of a metformin-mediated radiation response in SA-NH and FSa tumor cells treated under in vitro and in vivo growth conditions.

Murley JS, Miller RC, Senlik RR, Rademaker AW, Grdina DJ.

Int J Radiat Biol. 2017 Jul;93(7):665-675. doi: 10.1080/09553002.2017.1304592. Epub 2017 Mar 28.

4.

Very low doses of ionizing radiation and redox associated modifiers affect survivin-associated changes in radiation sensitivity.

Miller RC, Murley JS, Rademaker AW, Woloschak GE, Li JJ, Weichselbaum RR, Grdina DJ.

Free Radic Biol Med. 2016 Oct;99:110-119. doi: 10.1016/j.freeradbiomed.2016.07.009. Epub 2016 Jul 15.

PMID:
27427516
5.

NFκB and Survivin-Mediated Radio-Adaptive Response.

Grdina DJ, Murley JS, Miller RC, Woloschak GE, Li JJ.

Radiat Res. 2015 Apr;183(4):391-7. doi: 10.1667/RR14002.1. Epub 2015 Mar 12.

6.

CDK4-mediated MnSOD activation and mitochondrial homeostasis in radioadaptive protection.

Jin C, Qin L, Shi Y, Candas D, Fan M, Lu CL, Vaughan AT, Shen R, Wu LS, Liu R, Li RF, Murley JS, Woloschak G, Grdina DJ, Li JJ.

Free Radic Biol Med. 2015 Apr;81:77-87. doi: 10.1016/j.freeradbiomed.2014.12.026. Epub 2015 Jan 8.

7.

Metformin exhibits radiation countermeasures efficacy when used alone or in combination with sulfhydryl containing drugs.

Miller RC, Murley JS, Grdina DJ.

Radiat Res. 2014 May;181(5):464-70. doi: 10.1667/RR13672.1. Epub 2014 Apr 22.

8.

Protection from radiation-induced apoptosis by the radioprotector amifostine (WR-2721) is radiation dose dependent.

Ormsby RJ, Lawrence MD, Blyth BJ, Bexis K, Bezak E, Murley JS, Grdina DJ, Sykes PJ.

Cell Biol Toxicol. 2014 Feb;30(1):55-66. doi: 10.1007/s10565-014-9268-3. Epub 2014 Jan 24.

PMID:
24459009
9.

A survivin-associated adaptive response in radiation therapy.

Grdina DJ, Murley JS, Miller RC, Mauceri HJ, Sutton HG, Li JJ, Woloschak GE, Weichselbaum RR.

Cancer Res. 2013 Jul 15;73(14):4418-28. doi: 10.1158/0008-5472.CAN-12-4640. Epub 2013 May 7.

10.

CyclinB1/Cdk1 phosphorylates mitochondrial antioxidant MnSOD in cell adaptive response to radiation stress.

Candas D, Fan M, Nantajit D, Vaughan AT, Murley JS, Woloschak GE, Grdina DJ, Li JJ.

J Mol Cell Biol. 2013 Jun;5(3):166-75. doi: 10.1093/jmcb/mjs062. Epub 2012 Dec 12.

11.

A manganese superoxide dismutase (SOD2)-mediated adaptive response.

Grdina DJ, Murley JS, Miller RC, Mauceri HJ, Sutton HG, Thirman MJ, Li JJ, Woloschak GE, Weichselbaum RR.

Radiat Res. 2013 Feb;179(2):115-24. doi: 10.1667/RR3126.2. Epub 2012 Dec 13.

12.

SOD2-mediated adaptive responses induced by low-dose ionizing radiation via TNF signaling and amifostine.

Murley JS, Baker KL, Miller RC, Darga TE, Weichselbaum RR, Grdina DJ.

Free Radic Biol Med. 2011 Nov 15;51(10):1918-25. doi: 10.1016/j.freeradbiomed.2011.08.032. Epub 2011 Sep 3.

13.

Induction of cellular antioxidant defense by amifostine improves ventilator-induced lung injury.

Fu P, Murley JS, Grdina DJ, Birukova AA, Birukov KG.

Crit Care Med. 2011 Dec;39(12):2711-21. doi: 10.1097/CCM.0b013e3182284a5f.

14.

SOD2-mediated effects induced by WR1065 and low-dose ionizing radiation on micronucleus formation in RKO human colon carcinoma cells.

Murley JS, Kataoka Y, Miller RC, Li JJ, Woloschak G, Grdina DJ.

Radiat Res. 2011 Jan;175(1):57-65. doi: 10.1667/RR2349.1. Epub 2010 Nov 8.

15.

Amifostine metabolite WR-1065 disrupts homologous recombination in mammalian cells.

Dziegielewski J, Goetz W, Murley JS, Grdina DJ, Morgan WF, Baulch JE.

Radiat Res. 2010 Feb;173(2):175-83. doi: 10.1667/RR1982.1.

16.

Coactivation of ATM/ERK/NF-kappaB in the low-dose radiation-induced radioadaptive response in human skin keratinocytes.

Ahmed KM, Nantajit D, Fan M, Murley JS, Grdina DJ, Li JJ.

Free Radic Biol Med. 2009 Jun 1;46(11):1543-50. doi: 10.1016/j.freeradbiomed.2009.03.012. Epub 2009 Mar 24.

PMID:
19324081
17.

Amifostine induces antioxidant enzymatic activities in normal tissues and a transplantable tumor that can affect radiation response.

Grdina DJ, Murley JS, Kataoka Y, Baker KL, Kunnavakkam R, Coleman MC, Spitz DR.

Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):886-96. doi: 10.1016/j.ijrobp.2008.10.061.

18.

Amifostine reduces lung vascular permeability via suppression of inflammatory signalling.

Fu P, Birukova AA, Xing J, Sammani S, Murley JS, Garcia JG, Grdina DJ, Birukov KG.

Eur Respir J. 2009 Mar;33(3):612-24. doi: 10.1183/09031936.00014808. Epub 2008 Nov 14.

19.

WR-1065, the active metabolite of amifostine, mitigates radiation-induced delayed genomic instability.

Dziegielewski J, Baulch JE, Goetz W, Coleman MC, Spitz DR, Murley JS, Grdina DJ, Morgan WF.

Free Radic Biol Med. 2008 Dec 15;45(12):1674-81. doi: 10.1016/j.freeradbiomed.2008.09.004. Epub 2008 Sep 18.

20.

Maintenance of manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by repeated administration of the free thiol form of amifostine.

Murley JS, Nantajit D, Baker KL, Kataoka Y, Li JJ, Grdina DJ.

Radiat Res. 2008 May;169(5):495-505. doi: 10.1667/RR1194.1.

22.

Manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by the free thiol form of amifostine and tumor necrosis factor alpha.

Murley JS, Kataoka Y, Baker KL, Diamond AM, Morgan WF, Grdina DJ.

Radiat Res. 2007 Apr;167(4):465-74.

PMID:
17388698
23.

Flow cytometric analysis of phosphorylated histone H2AX following exposure to ionizing radiation in human microvascular endothelial cells.

Kataoka Y, Bindokas VP, Duggan RC, Murley JS, Grdina DJ.

J Radiat Res. 2006 Nov;47(3-4):245-57. Epub 2006 Sep 6.

25.

Radioprotectors: current status and new directions.

Grdina DJ, Murley JS, Kataoka Y, Zhou D, Seed TM.

Radiat Res. 2005 Jun;163(6):704-5. No abstract available.

PMID:
16044505
26.
27.

Interaction of amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC).

Khodarev NN, Kataoka Y, Murley JS, Weichselbaum RR, Grdina DJ.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):553-63.

PMID:
15380592
28.

Antimetastatic effectiveness of amifostine therapy following surgical removal of Sa-NH tumors in mice.

Grdina DJ, Kataoka Y, Murley JS, Swedberg K, Lee JY, Hunter N, Weichselbaum RR, Milas L.

Semin Oncol. 2002 Dec;29(6 Suppl 19):22-8.

PMID:
12577239
29.

Radioprotectants: current status and new directions.

Grdina DJ, Murley JS, Kataoka Y.

Oncology. 2002;63 Suppl 2:2-10. Review.

PMID:
12466639
30.
31.

Activation of the nuclear transcription factor kappaB (NFkappaB) and differential gene expression in U87 glioma cells after exposure to the cytoprotector amifostine.

Kataoka Y, Murley JS, Khodarev NN, Weichselbaum RR, Grdina DJ.

Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):180-9.

PMID:
12007958
32.
33.

Relationships between cytoprotection and mutation prevention by WR-1065.

Grdina DJ, Murley JS, Kataoka Y, Epperly W.

Mil Med. 2002 Feb;167(2 Suppl):51-3.

PMID:
11873516
34.

Method of RNA purification from endothelial cells for DNA array experiments.

Khodarev NN, Yu J, Nodzenski E, Murley JS, Kataoka Y, Brown CK, Grdina DJ, Weichselbaum RR.

Biotechniques. 2002 Feb;32(2):316, 318, 320. No abstract available.

35.

Inhibition of spontaneous metastases formation by amifostine.

Grdina DJ, Kataoka Y, Murley JS, Hunter N, Weichselbaum RR, Milas L.

Int J Cancer. 2002 Jan 10;97(2):135-41.

36.

Activation of NFkappaB and MnSOD gene expression by free radical scavengers in human microvascular endothelial cells.

Murley JS, Kataoka Y, Hallahan DE, Roberts JC, Grdina DJ.

Free Radic Biol Med. 2001 Jun 15;30(12):1426-39.

PMID:
11390188
37.

Amifostine: mechanisms of action underlying cytoprotection and chemoprevention.

Grdina DJ, Kataoka Y, Murley JS.

Drug Metabol Drug Interact. 2000;16(4):237-79.

PMID:
11201306
38.

Cytoprotection by WR-1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines.

Kataoka Y, Murley JS, Patel R, Grdina DJ.

Int J Radiat Biol. 2000 May;76(5):633-9.

PMID:
10866285
39.

Chemopreventive doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide.

Grdina DJ, Hunter N, Kataoka Y, Murley JS, Milas L.

Semin Oncol. 1999 Apr;26(2 Suppl 7):22-7.

PMID:
10348256
40.
41.

Effects of thiols on topoisomerase-II alpha activity and cell cycle progression.

Grdina DJ, Murley JS, Roberts JC.

Cell Prolif. 1998 Oct-Dec;31(5-6):217-29.

PMID:
9925989
42.

Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine.

Liu SC, Murley JS, Woloschak G, Grdina DJ.

Carcinogenesis. 1997 Dec;18(12):2457-9.

PMID:
9450496
44.
45.

Inhibition of topoisomerase II alpha activity in CHO K1 cells by 2-[(aminopropyl)amino]ethanethiol (WR-1065).

Grdina DJ, Constantinou A, Shigematsu N, Murley JS.

Radiat Res. 1994 Apr;138(1):44-52.

PMID:
8146299
46.

Effects of growth media on cell cycle progression in CHO cells exposed to the radioprotector WR-1065.

Murley JS, Grdina DJ, Meechan PJ.

Cell Prolif. 1992 Nov;25(6):643-50.

PMID:
1457610
47.

Accumulation of CHO cells in G2 phase following exposure to WR-1065.

Murley JS, Grdina DJ, Meechan PJ.

Radiat Res. 1991 May;126(2):223-8.

PMID:
2023993

Supplemental Content

Loading ...
Support Center